Skip to main content
Surrozen, Inc./DE logo

Surrozen, Inc./DE — Investor Relations & Filings

Ticker · SRZN ISIN · KYG2445M1033 US Professional, scientific and technical activities
Filings indexed 447 across all filing types
Latest filing 2026-05-14 Regulatory Filings
Country US United States of America
Listing US SRZN

About Surrozen, Inc./DE

https://www.surrozen.com

Surrozen, Inc. is a clinical-stage company that discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is pioneering a new class of targeted regenerative antibodies designed to stimulate the body's own repair mechanisms. These therapeutics aim to repair a broad range of tissues and restore organs damaged by serious diseases and injuries, with the goal of unlocking the body's regenerative power.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings
2026-05-14 English
ARS - Surrozen, Inc./DE (0001824893) (Filer)
Annual Report
2026-04-01 English
DEF 14A - Surrozen, Inc./DE (0001824893) (Filer)
Proxy Solicitation & Information Statement
2026-04-01 English
4 - Surrozen, Inc./DE (0001824893) (Issuer)
Director's Dealing
2026-03-26 English
S-8 - Surrozen, Inc./DE (0001824893) (Filer)
Registration Form
2026-03-23 English
S-3 - Surrozen, Inc./DE (0001824893) (Filer)
Registration Form
2026-03-23 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.